More Options, More Hope for Blood Cancer Patients.
Multiple myeloma affects an estimated 50,000 Americans, with approximately 15,000 new cases diagnosed each year. The cancer attacks plasma cells, or white blood cells, primarily in bone marrow -- which can damage the immune system's ability to fight against infection and disease. Myeloma tumors can also spread to multiple sites, causing bone destruction and fractures. Like Stevens' case, the disease is often discovered by chance and is not noticed until it has reached an advanced stage.
"Despite advances in treatment, only 30 percent of patients with advanced multiple myeloma typically live for more than five years after diagnosis," said Dr. Paul Richardson of the Dana-Farber Cancer Institute. "So it's important for patients to have access to new medicines."
Richardson is a leading investigator for new multiple myeloma treatment options. A recent study in the New England Journal of Medicine, led by Richardson, shows multiple myeloma patients treated with Velcade had a better chance at survival compared to patients who used the standard treatment.
For the full story and a photo, go to http://www.medialinkfeatures.com/home.aspx?Story=30711
ABOUT MEDIALINK FEATURES: Medialink Features provides free, ready-to-run, non-copyrighted news features, fillers and photos to newspaper and online editors. To download copy and photos, please visit http://www.medialinkfeatures.com.
NOTE TO EDITORS: All copy and photography is available for free and unrestricted use with Medialink Features (MF) dateline attribution.
|Printer friendly Cite/link Email Feedback|
|Date:||Aug 11, 2005|
|Previous Article:||AuEx Ventures Inc. Acquires Nevada Silver Project.|
|Next Article:||Kodak to Host Investor Event at Print '05.|